Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bupropion for smoking cessation. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' conclusions Nicotine withdrawal symptoms, including craving cigarettes, are extremely prevalent among patients attempting to quit and are often cited as the reason for relapse. Bupropion is an atypical antidepressant but its mechanism of action related to reduction of nicotine withdrawal symptoms is not clear. It is thought that bupropion ameliorates craving and other withdrawal symptoms by decreasing reuptake of neurotransmitters, including norepinephrine, dopamine, and serotonin in the brain. It is approved as a smoking cessation aid in North America, Australia, and Europe. Indexing Status Subject indexing assigned by CRD MeSH Bupropions; Smoking Cessation Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32011001319 Date abstract record published 05/10/2011 |